Siegfried at a Glance April 2020 About Us Who are we? Company - - PowerPoint PPT Presentation

Siegfried at a Glance

April 2020

About Us

3

Who are we?

› Company founded more than 140 years ago › Production of active pharmaceutical ingredients (Drug Substance), intermediates and finished dosage forms (Drug Products) › Unique selling proposition (USP): integrated service provider for development and manufacturing to the chemical and pharmaceutical industry › Number of employees (FTE): approx. 2500 › World-class service partner regarding Quality and Compliance › Listed on the Swiss Stock Exchange SIX

4

Why Siegfried?

› Bringing together our more than 140 years Pharma and Chemical heritage, we offer as an integrated partner benefit to our customers with more synergy, expertise and value. › We offer integrated supply of APIs and finished products. › Toughened stance by FDA: Siegfried for several years inspected with «no action indicated».

Drug Substances (DS) Drug Products (DP)

Drug discovery Dosage formulation Process development Intermediates API Clinical supplies Commercial Marketing & Distribution

Integration DS und DP

5

Our production network offers a unique combination of flexibility and integration for both, innovative and generic products

Our Mission Our Vision Our Values

7

Siegfried does matter to customers, patients and society – every day, everywhere

› Siegfried supplies approx. 200 APIs out of 1500 APIs approved by the FDA, thereby acting as a significant source to patients’ therapy continuity

1,300 200 Siegfried API portfolio Others

› Significant share of the annual global caffeine supply -> up to 1b people get in contact with Siegfried products each year › Based on our current portfolio, Siegfried serves approx. 40 million patients annually

Source: EvaluatePharma World Preview 2018, FDA orange book, Siegfried estimates

8

Our mission: we do matter to customers, patients and society

«With mastery of science and technology, we take the precious innovations of our pharmaceutical customers to industrial scale and manufacture safe drugs for patients worldwide»

9

Our vision: we aim for industry leadership

«Siegfried is the most trusted partner of the pharmaceutical industry and the global leader in the CDMO space – because… … we are the strongest team running the most competitive network»

10

Our values: we strive for outstanding performance

Excellence

«We excel in everything we do»

Passion

«We deeply care about what we do and how we do it»

Integrity

«We act responsibly, reliably, respectfully and live up to our

• wn standards»

Quality

«We do it right first time»

Sustainability

«We do not only think about tomorrow, but far beyond»

«Our values and leadership principles are the basis to build the strongest team in the industry»

11

Our leadership values are the basis to build the strongest team in the industry

Lead and develop people Empower people Manage performance Lead and develop

• rganization

Drive business growth Excel

• perationally

Drive results Make decisions Drive implementation Be a role model Act reliably Embody and exemplify values and business standards Manage change and innovation Lead change process Foster innovation Deliver service and value Ensure quality Focus on customers Excellence Passion Integrity Quality Sustainability

Our History

13

History

1873 Pharmacist Samuel Benoni Siegfried founds a company with 12 employees as a supplier to pharmacies 1904 Conversion into a joint stock corporation 1928 Founding of Ganes Chemical Works,

• Inc. (NJ, USA)

1973 Quotation on the Swiss Stock Exchange (SWX) in Basel 1991 Focus on development and custom manufacturing

14

History

2001 Building of two core divisions: Siegfried and Sidroga Integration of Ganes into the Siegfried Group = Siegfried (USA) Inc. 2005 Acquisition of Penick Corporation in New Jersey (USA) 2007 Launch of a new pharmaceutical production facility in Malta Sale of the Sidroga Division Sale of the biotech activities 2008 Sale of the pharmaceutical production site in Zofingen

15

History

2010 Definition of new strategy “Transform” 2012 Acquisition of Alliance Medical Products (AMP) in Irvine (CA, USA) 2013 Construction of new production site Nantong (CN) and Zofingen (CH) 2014 Acquisition of Hameln Pharma in Hameln (DE) 2015 Acquisition of BASF sites in Minden (DE), Evionnaz (CH) and St. Vulbas (FR) 2016 Definition of new strategy “Evolve” 2018 Acquisition of the drug product manufacturing facility of Arena in Zofingen (CH)

Our Management

17

Management – Board of Directors

› Dr. Andreas Casutt › Chairman › Colin Bond › Prof. Dr. Wolfram Carius › Dr. Martin Schmid › Isabelle Welton › Ulla Schmidt › Reto A. Garzetti

18

Management – Executive Committee

› Dr. Wolfgang Wienand › Chief Executive Officer › Dr. Reto Suter › Chief Financial Officer › Arnoud M. Middel › Global Head Human Resources › Marianne Späne › Global Head Business Development, Marketing & Sales › Dr. René Imwinkelried › Global Head Technical Operations › Jürgen Roos › Chief Scientific Officer

Financials

20

Net Sales

CHF million 2019 2018 Change

Drug Substances 638.6 595.5 +7.2% (+9.0% in LC) Drug Products 194.9 198.8

• 2.0% (+0.5% in LC)

Total 833.5 794.3 +4.9% (+6.9% in LC)

77% 23% Drug Substances Drug Products

Net sales split 2019

21

Business Development

315.3 480.6 717.7 750.5 794.3 833.5 100 200 300 400 500 600 700 800 900 2014 2015 2016 2017 2018 2019

Net sales (in CHF million)

22

Business Development

Share price development from January 1, 2015 to December 31, 2019